^
Association details:
| Biomarker: | RET rearrangement |
|---|---|
| Cancer: | Thyroid Gland Carcinoma |
| Drug: | AZD1480 (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines
Excerpt:
Specifically, we analyzed PTC-derived TPC-1 (RET/PTC1 rearrangement), MTC-derived MZ-CRC1 (RET M918T mutation) and TT (RET C634W mutation) cell lines….AZD1480 inhibited the growth of all RET-mutated/rearranged cell lines after 1 (MZ-CRC1, TT) and 2 days (TPC-1) of treatment (p<0.0001; Fig. 1A) and minimally decreased the growth of C643, while having no effect on K1 (Fig. S1).
DOI:
10.1371/journal.pone.0046869
